On January 28, 2020, the FH Foundation and some of our amazing community members and leaders, who are FH Advocates for Awareness, will go to Capitol Hill to ask our elected representatives for their continued support in prioritizing familial hypercholesterolemia (FH) as a public health concern and … Read More
Advocacy and Policy
The FH Foundation is a true partnership of individuals and families impacted by FH, and the healthcare professionals who diagnose and treat FH. Together, we are raising awareness of FH, driving improved diagnosis, making sure individuals know their treatment options and opportunities for clinical … Read More
On May 7, 2019 FH Advocate, April Donelson, chose to spend her birthday on Capitol Hill, advocating to make familial hypercholesterolemia (FH) a public health priority with Florida and Texas Congressional leaders. April shared “Ryan’s story” to make sure everyone understands the importance … Read More
Affordable prescription drugs are necessary so individuals can benefit from advances in medicine to treat conditions such as familial hypercholesterolemia. Medical research and innovation make it possible to actually prevent or delay heart disease in people born with FH. All it takes is early diagnosis … Read More
Ask the Pharmacy – Are you getting the lowest cost for your PCSK9 inhibitor?
The manufacturers of both PCSK9 inhibitors, Praluent and Repatha, have lowered the list price for these cholesterol-lowering treatments by 60% to $5,850 per year. As we reported in February, the FH Foundation continues … Read More
The FH Foundation welcomes Sanofi and Regeneron’s announcement today to lower the list price of its LDL cholesterol lowering treatment, the PCSK9 inhibitor Praluent, to $5,850 annually. This brings the list price of Praluent in line with Amgen’s PCSK9 inhibitor, Repatha, which was lowered … Read More
The FH Foundation went to Capitol Hill on January 28-29 to raise awareness of Familial Hypercholesterolemia among our nation’s elected officials, and advocate for Federal funding for FH research.
Our 2019 class of 25 new volunteer FH Advocates for Awareness held 36 meetings with Congressional Offices … Read More
Katherine Wilemon, Founder and CEO, Cat Davis Ahmed, Vice President of Policy and Outreach, and several FH Foundation board members participated in a workshop convened by the National Heart Lung and Blood Institute (NHLBI) in November 2018. The goal of the workshop was to develop a multidisciplinary … Read More
“Great scientific progress, efficacious therapies, and elegantly written guidelines don’t always end up helping the people they were intended to serve. This is a sobering fact, and in many ways, is the story of familial hypercholesterolemia,” asserted Katherine Wilemon, Founder and CEO of … Read More
I met Dr. Roger Williams in 1985 when I visited the University of Utah from Rockefeller University, where I was a post-doctoral fellow in Jan Breslow’s laboratory. Jan arranged for me to learn Southern blotting with Ray White and Jean-Marc Lalouel at the Howard Hughes Medical Institute. Jean-Marc … Read More